Junior Lelio de Souza sold $623K of AFYA

Junior Lelio de Souza (Vice President) sold 41,541 shares of Afya Ltd (AFYA) at $15.00 ($0.62M total) on 2026-06-26.

Original reporting
SEC EDGAR · Junior Lelio de Souza
Published Jun 30, 2026, 8:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AFYA
Neutral
medium confidence
Mentioned
$AFYA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AFYANeutralLow
01

Why it matters

The disclosed fact is the size and price of the insider’s open-market sale; it does not include new operational, financial, or regulatory information about Afya.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to drive a durable repricing.

03

What to watch

The filing notes no 10b5-1 plan; traders may still treat the sale as marginally more informative than a typical planned sale, but the article provides no additional context (e.g., tax, diversification, or follow-on buys).

Relevance 5/10Novelty 3/10Timing: Form 4 filed June 30; sale executed June 26

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Afya Ltd.

Company-level read

Ticker impact

$AFYANeutralMedium confidence
Context

Afya Ltd VP Junior Lelio de Souza sold 41,541 shares in an open-market transaction for about $623K, per Form 4 filed June 30.

Expected impact

Low near-term impact; any effect is likely short-lived unless repeated or paired with other negative disclosures.

Evidence & confidence

The filing is a disclosed sale (not a buy), but it is not tied to new company fundamentals, guidance, or regulatory/operational events in the text.

Market effects

No sector read-across; this is a single-company insider transaction with no stated operational change.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/tax and may not reflect bearish expectations, especially without a stated negative catalyst.

Key entities

  • Afya Ltd

    Subject of the Form 4 insider transaction; VP sold 41,541 shares at $15.00/share.

  • Junior Lelio de Souza

    Vice President who executed the sale; holdings after transaction were 36,204 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AFYAMed

Afya Limited (AFYA) Q3 Revenue Rises 6.1% to R$985.2M

Afya Limited reported Q3 2026 revenue of R$985.2M, up 6.1% YoY, and Adjusted EBITDA of R$433.8M, up 8.7%. Nine-month net income rose 6.9% to R$634.0M. The company reaffirmed its full-year 2026 guidance. The next catalysts are shareholder and regulatory decisions on its proposed merger with Yduqs.

$AFYAHigh

Afya Ltd (AFYA): Financial results for Q3 2026

Afya Ltd (AFYA) furnished an SEC Form 6-K — earnings release. Afya Limited Announces Third Quarter and Nine Months 2026 Financial Results Strong Cash Conversion and Continued Earnings Growth Full-Year 2026 Guidance Reaffirmed Belo Horizonte, Brazil, November 12, 2026 – Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the l

$AFYAHigh

BofA upgrades Afya stock rating on exam rule changes

BofA upgraded Afya (AFYA) to Buy, lowering its price target to $16. The firm cited Afya's resilient student base, low leverage, and recent exam rule changes as reasons. Afya trades at $10.24, near its 52-week low, with a 6.32 P/E ratio and 30% free cash flow yield. Afya reported 6% Q2 and 7% H1 revenue growth, with net income rising 14% and 7% respectively. JPMorgan also upgraded Afya to Overweight, expecting merger synergies.